Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Sunday 05.04.2020 at 10:00 AM CEST
Settings

Settings

1. WO1996003993 - MODULATION OF THYMOCYTE AND T CELL FUNCTIONAL ACTIVITY

Publication Number WO/1996/003993
Publication Date 15.02.1996
International Application No. PCT/US1995/009915
International Filing Date 07.08.1995
Chapter 2 Demand Filed 05.03.1996
IPC
A61K 38/22 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
G01N 33/50 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
CPC
A61K 31/5685
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
565not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
568substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
5685having an oxo group in position 17, e.g. androsterone
A61K 38/225
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
225Calcitonin gene related peptide
G01N 33/5011
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
5005involving human or animal cells
5008for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
5011for testing antineoplastic activity
Applicants
  • THE ROCKEFELLER UNIVERSITY [US/US]; 1230 York Avenue New York, NY 10021-6399, US (AllExceptUS)
  • BULLOCH, Karen [US/US]; US (UsOnly)
  • McEWEN, Bruce, S. [US/US]; US (UsOnly)
Inventors
  • BULLOCH, Karen; US
  • McEWEN, Bruce, S.; US
Agents
  • FEHLNER, Paul, F. ; Klauber & Jackson Continental Plaza 411 Hackensack Avenue Hackensack, NJ 07601, US
Priority Data
08/286,86405.08.1994US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) MODULATION OF THYMOCYTE AND T CELL FUNCTIONAL ACTIVITY
(FR) MODULATION DE L'ACTIVITE FONCTIONNELLE DE THYMOCYTES ET DE LYMPHOCYTES T
Abstract
(EN)
The present invention relates to modulation of cell mediated immune responses, and to modulation or inhibition of thymocyte cancers or thymomas. In a first aspect, the present invention is directed to a method for suppressing an immune response by administering dehydroepiandrosterone (DHEA). In another aspect, the invention relates to a method for enhancing an immune response comprising administering an amount of an inhibitor of calcitonin gene related peptide (CGRP), such as the CGRP antagonist CGRP8-37, or an amount of an inhibitor of DHEA. The invention also provides a method for treating a thymic cancer or thymoma comprising administering an amount of calcitonin gene related peptide (CGRP) effective to induce apoptosis of thymic cancer or thymoma cells. The invention further provides a method for preventing tissue damage comprising administering an amount of an inhibitor of CGRP to inhibit apoptosis of cells in the area of the tissue damage. The invention also relates to a method for identifying an agent capable of inhibiting CGRP-mediated apoptosis.
(FR)
La présente invention concerne la modulation des réponses immunitaires de cellules et la modulation ou l'inhibition de cancers des thymocytes ou thymomes. Selon un premier aspect, le présente invention concerne un procédé pour supprimer une réponse immune en administrant de la déshydroépiandrostérone (DHEA). Selon un autre aspect, l'invention concerne un procédé pour augmenter une réponse immune, consistant à administrer une certaine quantité d'un inhibiteur du peptide apparenté au gène de la calcitonine (CGRP) comme, par exemple l'antagoniste du CGRP qu'est CGRP8-37 ou une certaine quantité d'un inhibiteur de la DHEA. L'invention concerne également un procédé pour traiter un cancer du thymus ou thymone consistant à administrer une quantité de CGRP suffisante pour induire une apoptose des cellules du cancer du thymus ou thymome. L'invention concerne en outre un procédé pour empêcher des atteintes aux tissus, consistant à administrer une quantité d'inhibiteur du CGRP suffisante pour inhiber l'apoptose de cellules dans la région de l'atteinte aux tissus. L'invention concerne encore un procédé pour identifier un agent capable d'inhiber l'apoptose due au CGRP.
Latest bibliographic data on file with the International Bureau